Vimseltinib Oral Formulation for Uniform CSF-1R Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective small-molecule CSF-1R inhibitors and formulations thereof, particularly oral dosage forms, to treat disorders associated with the proliferation of tumor-associated macrophages (TAMs) in solid tumors and mesenchymal tumors like tenosynovial giant cell tumor (TGCT), addressing issues of off-target toxicity and plasma CSF-1 level increases in existing therapies, while ensuring content uniformity for consistent drug delivery.
Innovation Solution
Pharmaceutically acceptable formulations comprising a compound represented by Formula (I), in the form of a free base or pharmaceutically acceptable salt, combined with excipients such as fillers, disintegrants, and lubricants, to create uniform oral dosage forms and capsules, ensuring consistent delivery of vimseltinib for treating conditions like TGCT, GVHD, neurodegenerative diseases, and various cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CSF-1R inhibitors are used, then CSF-1R inhibition is achieved, but off-target toxicity occurs due to inhibition of closely related Type III receptor tyrosine kinases (KIT, PDGFRα/β, and FLT3)
Solution Approach 1:
The patent applies parameter changes by optimizing the chemical structure of small-molecule inhibitors to achieve selective binding to CSF-1R. The compound of Formula (I) and its salts are designed with specific molecular parameters (substituents R1-R6, core structure) that enable selective interaction with CSF-1R while avoiding off-target binding to KIT, PDGFRα/β, and FLT3 kinases, thereby improving selectivity without causing off-target toxicity
2Reliability
If antibodies targeting CSF-1R are used, then specificity is improved, but plasma levels of CSF-1 increase >10,000-fold due to blockade of CSF-1 clearance
Solution Approach 1:
The patent extracts the problematic function of CSF-1 clearance blockade by using small-molecule inhibitors that directly block the CSF-1R kinase activity without interfering with CSF-1 ligand clearance mechanisms. The small-molecule compounds of Formula (I) inhibit the receptor tyrosine kinase activity while allowing natural CSF-1 degradation pathways to remain functional, thus achieving specificity without causing excessive plasma CSF-1 accumulation
Solution Approach 2:
The patent uses small-molecule compounds as intermediaries that can penetrate cell membranes and directly inhibit CSF-1R kinase activity intracellularly. These small-molecule mediators (Formula (I) and salts) provide a different mechanism compared to antibodies, achieving CSF-1R inhibition through direct kinase blockade rather than receptor occupancy, thereby avoiding the clearance blockade effect
3Ease of manufacture
If content uniformity is not ensured in formulations, then manufacturing is simpler, but patient receives unreliable dose and exposure to active substance
Solution Approach 1:
The patent applies preliminary action by incorporating specific excipients and formulation components (fillers, disintegrants, lubricants, glidants) into the tablet formulation before manufacturing. The compound of Formula (I) is pre-mixed with these excipients in controlled amounts to ensure uniform distribution of the active substance throughout the formulation, guaranteeing content uniformity while maintaining manufacturing feasibility through established pharmaceutical processes
Data Source
AI summary
Described herein, in part, are pharmaceutically acceptable formulations comprising a compound represented by Formula (I) and methods of preparing and using the formulations: